CXCL12 and breast carcinoma: Similarly, in breast cancer, iCAFs recruit Tregs and induce an immunosuppressive microenvironment through the CXCL12/CXCR4 axis, ultimately contributing to resistance to anti‐PD‐1 therapy [196].